Clinical Trial – Monitoring and Treatment of Relapsed Leukemia – Leukemia

Prescient Therapeutics, Ltd. is running a clinical trial to test drugs called PTX-200 and Cytarabine to treat acute leukemia. A phase I-II open label study of PTX-200 in combination with cytarabine in the treatment of relapsed or refractory acute leukemia.

The drugs are PTX-200 and Cytarabine.

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I-II Study of Triciribine Phosphate Monohydrate (PTX-200) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
Actual Study Start Date : September 2016
Estimated Primary Completion Date : March 2018
Estimated Study Completion Date : September 2018

Contacts

Contact: Mandeep Grewal mandeep@ptxtherapeutics.com

NCT Number

NCT number: NCT02930109

For enrollment please visit www.clinicaltrials.gov.

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.